DE2358906C2 - Verfahren zur Herstellung von Tabletten - Google Patents
Verfahren zur Herstellung von TablettenInfo
- Publication number
- DE2358906C2 DE2358906C2 DE2358906A DE2358906A DE2358906C2 DE 2358906 C2 DE2358906 C2 DE 2358906C2 DE 2358906 A DE2358906 A DE 2358906A DE 2358906 A DE2358906 A DE 2358906A DE 2358906 C2 DE2358906 C2 DE 2358906C2
- Authority
- DE
- Germany
- Prior art keywords
- mixture
- tablets
- lithium carbonate
- particle size
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 21
- 239000000203 mixture Substances 0.000 claims description 32
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 26
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 10
- 229910052744 lithium Inorganic materials 0.000 claims description 10
- 125000005908 glyceryl ester group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 150000005691 triesters Chemical class 0.000 claims description 7
- 150000005690 diesters Chemical class 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 5
- 239000004606 Fillers/Extenders Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 239000002706 dry binder Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000004898 kneading Methods 0.000 claims description 2
- 210000001217 buttock Anatomy 0.000 claims 1
- 238000009481 moist granulation Methods 0.000 claims 1
- 239000000463 material Substances 0.000 description 8
- 229910003002 lithium salt Inorganic materials 0.000 description 7
- 159000000002 lithium salts Chemical class 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000005029 sieve analysis Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000220479 Acacia Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 101001034830 Mus musculus Interferon-induced transmembrane protein 5 Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5467172A GB1450536A (en) | 1972-11-27 | 1972-11-27 | Method of making tablets |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2358906A1 DE2358906A1 (de) | 1974-06-06 |
| DE2358906C2 true DE2358906C2 (de) | 1983-12-22 |
Family
ID=10471737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2358906A Expired DE2358906C2 (de) | 1972-11-27 | 1973-11-27 | Verfahren zur Herstellung von Tabletten |
Country Status (9)
| Country | Link |
|---|---|
| BE (1) | BE807801R (enExample) |
| CA (1) | CA1012887A (enExample) |
| CY (1) | CY914A (enExample) |
| DE (1) | DE2358906C2 (enExample) |
| GB (1) | GB1450536A (enExample) |
| IE (1) | IE38550B1 (enExample) |
| MT (1) | MTP755B (enExample) |
| NL (1) | NL7316079A (enExample) |
| ZA (1) | ZA738856B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MTP930B (en) * | 1982-04-30 | 1984-04-10 | Delandale Labs Ltd | Substained release lithium-containing tablets and method for their manufacture |
| CN113521024A (zh) * | 2017-04-17 | 2021-10-22 | 上海葆隆生物科技有限公司 | 一种碳酸锂缓释片 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1209093A (en) * | 1968-07-16 | 1970-10-14 | Delandale Lab Ltd | Pharmaceutical preparation |
-
1972
- 1972-11-27 GB GB5467172A patent/GB1450536A/en not_active Expired
-
1973
- 1973-11-20 CY CY914A patent/CY914A/xx unknown
- 1973-11-20 ZA ZA738856A patent/ZA738856B/xx unknown
- 1973-11-23 NL NL7316079A patent/NL7316079A/xx not_active Application Discontinuation
- 1973-11-26 BE BE138166A patent/BE807801R/xx active
- 1973-11-26 CA CA186,637A patent/CA1012887A/en not_active Expired
- 1973-11-26 MT MT755A patent/MTP755B/xx unknown
- 1973-11-27 DE DE2358906A patent/DE2358906C2/de not_active Expired
- 1973-11-27 IE IE2147/73A patent/IE38550B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE807801R (fr) | 1974-03-15 |
| GB1450536A (en) | 1976-09-22 |
| MTP755B (en) | 1974-05-09 |
| IE38550B1 (en) | 1978-04-12 |
| DE2358906A1 (de) | 1974-06-06 |
| AU6290173A (en) | 1975-05-29 |
| CY914A (en) | 1977-12-23 |
| ZA738856B (en) | 1974-10-30 |
| IE38550L (en) | 1974-05-27 |
| NL7316079A (enExample) | 1974-05-29 |
| CA1012887A (en) | 1977-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69802543T3 (de) | Verbesserte multipartikel-tablette mit schnellauflösbarkeit | |
| DE69407404T2 (de) | Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung | |
| DE3689983T2 (de) | Arzneimittel mit langsamer Wirkstofffreisetzung. | |
| DE69400356T2 (de) | Quervernetzte amylose als bindemittel/sprengmittel fuer tabletten | |
| DE69110592T2 (de) | Pharmazeutische Zubereitung mit verbessertem Geschmack, poröse Partikel enthaltend, und deren Herstellungsmethode. | |
| AT394310B (de) | Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge | |
| DE69311395T2 (de) | Sphäroidische Arzneimittelformulierung | |
| DE69829042T2 (de) | Nicotinsäurezusammensetzungen enthaltender Starterkit | |
| DE1292783B (de) | Verfahren zum Herstellen einer Tablette mit Depotwirkung | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE69327745T2 (de) | Tablette zur langsamen Freisetzung von Natriumvalproat | |
| DE2706660A1 (de) | Ascorbinsaeure enthaltende granulate und verfahren zu ihrer herstellung | |
| DE1935879C3 (de) | Verfahren zur Herstellung eines pharmazeutischen Lithium-Präparates | |
| DE69214310T2 (de) | Pranoprofen enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe | |
| EP0146863A2 (de) | Orale retardierte Acetylsalicylsäureformulierungen | |
| DE69307807T2 (de) | Naproxen-Tabletten mit gesteuerter Wirkstoffabgabe | |
| DE2358906C2 (de) | Verfahren zur Herstellung von Tabletten | |
| DE69626676T2 (de) | Schnell freisetzende tablette enthaltend tolfenaminsäure oder ein pharmazeutisch verträgliches salz davon | |
| DE3019032A1 (de) | Antacider wirkstoff auf magnesium-aluminiumhydroxid-basis, verfahren zu dessen herstellung und dessen verwendung bei der bekaempfung von magenerkrankungen und der hyperaziditaet | |
| DE69224793T2 (de) | Magnesiumhaltiges Arzneimittel mit verlängerter Wirkstoffabgabe | |
| DE69628994T2 (de) | Futterzusatz für wiederkäuer | |
| DD202017A5 (de) | Verfahren zur herstellung von calciumoxaprozin | |
| DE3942131C2 (de) | Pharmazeutisches Trimebutin-haltiges Präparat mit verlängerter Wirkstoff-Freisetzung und Verfahren zur Herstellung | |
| DE3048154C2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8126 | Change of the secondary classification |
Ipc: A61K 9/22 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |